CD34 and acute myeloid leukemia: However, given that tunicamycin at low doses appears to be well tolerated in vivo in mouse models [13, 14], and was not markedly cytotoxic to normal human CD34+ bone-marrow cells, our findings suggest that further assessment of FLT3 inhibitor/tunicamycin combinations in preclinical AML models may be warranted.